Welcome to our dedicated page for Misonix news (Ticker: MSON), a resource for investors and traders seeking the latest updates and insights on Misonix stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Misonix's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Misonix's position in the market.
Misonix, Inc. (Nasdaq: MSON), a leader in minimally invasive therapeutic ultrasonic medical devices, announced its participation in the upcoming Cantor Virtual Global Healthcare Conference. The presentation will be led by CEO Stavros Vizirgianakis and CFO Joe Dwyer on September 17 at 11:20 a.m. ET. Additionally, management will engage in one-on-one virtual meetings with institutional investors throughout the day. Misonix is committed to innovation in medical technology, enhancing outcomes with products like BoneScalpel and TheraSkin.
Misonix (MSON) reported its fourth quarter and full year 2020 financial results, highlighting a 40.6% revenue increase to $13.7 million in Q4 and a 60.8% rise to $62.5 million for the year. However, net losses grew to $8.5 million for Q4 and $17.4 million for the year, impacted by COVID-19 and increased operating expenses from its Solsys acquisition. The gross profit margin remained strong at 68.8% for Q4 and 70.0% for the year. Misonix is focusing on cash preservation and operational efficiency as it navigates ongoing pandemic challenges.
Misonix, Inc. (NASDAQ: MSON) is set to announce its fiscal 2020 fourth quarter financial results on September 3, 2020, after market close. The company anticipates reporting approximately $13.5 million in Q4 revenue and approximately $62.3 million in total revenue for the fiscal year. As of June 30, 2020, Misonix held approximately $38 million in cash. A conference call will follow the results announcement at 4:30 p.m. ET and will be accessible to the public via live webcast.
Misonix, Inc. (Nasdaq: MSON) will participate in the 40th Annual Canaccord Genuity Growth Conference. The presentation will take place virtually on August 12 at 10:30 a.m. ET, featuring CEO Stavros Vizirgianakis and CFO Joe Dwyer. Investors can engage in one-on-one virtual meetings on August 12 and 13.
Misonix specializes in minimally invasive ultrasonic medical devices for surgical applications and wound care. The company is dedicated to enhancing clinical outcomes through innovative technology.
Misonix, Inc. (MSON) reported a preliminary fourth quarter revenue of approximately $13.5 million, up from $9.8 million year-over-year. The acquisition of Solsys Medical is reflected, with pro forma revenue down 23% compared to Q4 FY2019. Full year revenue reached about $62.3 million, marking a 60.6% increase from the previous year. Challenges due to COVID-19 impacted surgical and wound revenues, with declines of 36% and 11%, respectively. The company has around $38 million in cash as of June 30, 2020.
Misonix, Inc. (Nasdaq: MSON) announced participation in the 17th Annual Craig Hallum Institutional Investor Conference on May 27, 2020. The event will be virtual, featuring Misonix President and CEO Stavros Vizirgianakis and CFO Joe Dwyer engaging with institutional investors throughout the day. Investors can access the presentation in the Company’s Investor Relations section. Misonix specializes in minimally invasive ultrasonic medical devices aimed at improving clinical outcomes across various surgical fields.
Misonix (NASDAQ: MSON) will announce its fiscal 2020 third-quarter financial results on May 11, 2020, after market close. A conference call and webcast will follow at 4:30 p.m. ET, accessible to the public. The company specializes in minimally invasive ultrasonic medical devices, primarily for surgical applications in various medical fields, including neurosurgery and wound care. Misonix has integrated its SonicOne product with the TheraSkin cellular skin substitute to enhance wound treatment solutions.